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Abstract
Photodynamic therapy is a well-established and clinically approved treatment for several types of cancer. Antineoplastic photo-
dynamic therapy is based on photosensitizers, i.e., drugs that absorb photons translating light energy into a chemical potential 
that damages tumor tissues. Despite the encouraging clinical results with the approved photosensitizers available today, the 
prolonged skin phototoxicity, poor selectivity for diseased tissues, hydrophobic nature, and extended retention in the host 
organism shown by these drugs have stimulated researchers to develop new formulations for photodynamic therapy. In this 
context, due to their amphiphilic characteristic (compatibility with both hydrophobic and hydrophilic substances), liposomes have 
proven to be suitable carriers for photosensitizers, improving the photophysical properties of the photosensitizers. Moreover, 
as nanostructured drug delivery systems, liposomes improve the efficiency and safety of antineoplastic photodynamic therapy, 
mainly by the classical phenomenon of extended permeation and retention. Therefore, the association of photosensitizers with 
liposomes has been extensively studied. In this review, both current knowledge and future perspectives on liposomal carriers 
for antineoplastic photodynamic therapy are critically discussed.
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The cytotoxic effects of photodynamic therapy (PDT) 
on tumor tissues were first described at the beginning of 
the 20th century, but this therapy would be widely used in 
medical services only in the 1990s. Nowadays, PDT is a 
well-established antineoplastic therapy with several com-
mercially available protocols approved for different types 
of cancer. It has proven to be a cost-effective treatment 
compared to other traditional therapies (1), and this may be 
due to the low costs of PDT equipment and hospital facilities 
in comparison to the requirements for other therapies such 
as surgery, chemotherapy and radiotherapy. All of these 
advantages have stimulated the emergence of several 
centers for PDT treatment worldwide, including emerging 
countries such as Brazil and China (1,2). 
PDT is based on the delivery of photosensitizer drugs 
(PSs) to biological targets, which are then irradiated with 
light at specific wavelengths (3). There are many different 
kinds of PS, each one with its specific excitation wavelength. 
However, the useful spectral window for PDT application in 
biological tissues is limited by the absorption of light by both 
water - at wavelengths above 1000 nm - and hemoglobin/
myoglobin - at wavelengths below 600 nm (4). Therefore, 
the excitation wavelength must be in the 600-1000-nm 
range so that the light can cross the cells without being ab-
sorbed before reaching the PS. During PS photoactivation, 
an excitable electron is promoted to a higher energy level 
(antibonding orbital) and the PS reaches the first excited 
singlet state. This excited state decays to a lower energy 
level by emitting fluorescence or, alternatively, it decays 
by the process of intersystem crossing to a state named 
triplet (3). This triplet state is long lived and, because of this 
feature, it is able to react with triplet oxygen molecules and 
other biomolecules or to emit phosphorescence (3). When 
it transfers energy to triplet oxygen, very reactive species 
called singlet oxygen are produced. Both the triplet PS 
and the singlet oxygen are unstable molecules and for this 
reason they are responsible, in biological tissues, for the 
damage to biomolecules - mainly polyunsaturated lipids, 
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nucleic acids and proteins - after PS irradiation. Didactically, 
the direct reaction between triplet PS and a biomolecule 
is called the Type 1 reaction and this process leads to PS 
blanching; the production of singlet oxygen by the triplet 
PS is called the Type 2 reaction and it regenerates the 
ground-state PS (4) (Figure 1). 
PSs are classified as 1st, 2nd, and 3rd generation, or 
according to their respective chemical class (e.g., phenoti-
azine, porphyrins, chlorins, phthalocyanines) (3,5). Despite 
their effectiveness on tumor cells, the majority of these PSs 
have shown limitations to their use in clinical applications, 
which include extended retention in the host organism, 
substantial skin phototoxicity, low solubility in physiologi-
cal solutions, low selective accumulation in the diseased 
tissue, and inappropriate half-lives within tissue, impairing 
the optimization of illumination schedules (6). 
Several approaches were tested in order to avoid the 
undesired effects described above and the employment of 
drug delivery systems has then emerged as a new strat-
egy to improve the efficacy and safety of PDT. The drug 
delivery system is expected to incorporate high amounts 
of the PS without loss or alteration of its activity, to selec-
tively accumulate the PS in the diseased tissue, to deliver 
therapeutic amounts of PS to the target site, to protect 
the PS from degradation and from premature clearance, 
to minimize drug leakage during transit to target, and to 
facilitate PS interaction with cells; moreover, the delivery 
system must be biodegradable and should induce little or 
no immunogenicity (7).
In this context, it is not by chance that liposomes are 
Figure 1. When excited by light at a specific wavelength, the photosensitizer (PS) reaches its first excited singlet state. This state 
can decay by emitting fluorescence or, alternatively, it reaches the more stable excited triplet state through the intersystem crossing 
process. The PS in its triplet state can directly react with biomolecules (Type 1 reaction) or with the triplet oxygen producing the singlet 
oxygen (Type 2 reaction), which is much more oxidative than the triplet oxygen. Although both of these reactions can damage cells, 
the most significant damage is induced by Type 2 reactions. On the right side is a photograph showing a patient being laser-irradiated: 
fluorescence emission can be used for detecting the photosensitizer. 
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one of the most extensively studied drug delivery systems 
and represent a significant proportion of nanotechnology 
research in biomedicine today (8). These lipid nanopar-
ticles possess several features that are desired in a drug 
delivery system (9). Moreover, a large number of investi-
gations on the subject of liposomes have provided some 
crucial improvements in liposomal formulations, such as: 
prolonged circulation time in the bloodstream (PEGylated 
liposomes), improved dose and target selectivity (immuno-
liposomes, tumor-specific ligands, pH-sensitive and mag-
netoliposomes) and enhanced cell internalization (cationic 
liposomes) (7). However, despite their advantages, some 
kinds of liposomes are not in current use inasmuch as 
none or few studies showing their application for PDT have 
been reported since their first 
description. Therefore, only 
those liposome approaches 
showing encouraging in vivo 
results for anticancer PDT 
are described in the pres-
ent review. In addition, new 
perspectives on liposome-
based antineoplastic PDT are 
discussed. 
General aspects of 
liposomes
Liposomes are artificial 
vesicles generally ranging in 
size from 20 to 1000 nm (8), 
composed mainly of a phos-
pholipid bilayer surrounding 
an aqueous core (see Figure 
2). The phospholipids em-
ployed to produce liposomes 
can be synthetic or derived 
from natural sources. Their 
structure is characterized 
by 2 regions - polar head 
and hydrophobic long hydro-
carbon acyl chains - which 
can be modified to suit the 
desired liposome size and 
shape (9).
The structures of both 
the hydrophobic and hydro-
philic regions of a phospho-
lipid determine its shape. 
For example, phospholipids 
such as phosphatidylcho-
line, phosphatidylserine and 
sphingomyelin are known to 
be cylindrical-shaped lipids 
because the diameter of their 
polar group is similar to that of their hydrophobic part, caus-
ing them to spontaneously form bilayers when dispersed 
in an aqueous medium. On the other hand, phosphati-
dylethanolamine and cardiolipin are cone-shaped lipids 
because the diameter of their polar head is significantly 
different from that of their hydrophobic region - these lipids 
are also called non-bilayer lipids as they preferentially form 
a hexagonal structure (depending on the conditions of the 
medium) (9).
Since there is a wide variety of phospholipids, it is 
possible to change the liposome size, charge, and surface 
properties by adding new ingredients to the lipid mixture. 
Therefore, it is important to select phospholipid combina-
tions and to standardize appropriate PS concentrations 
B
Figure 2. A, Liposomes are basically composed of a phospholipid bilayer surrounding an aque-
ous core; they function as containers in which several chemically different compounds can be 
entrapped or to which they can be attached. Hydrophobic drugs can be associated with the lipid 
membrane while the hydrophilic ones can be dissolved in the aqueous core. B, Transmission 
electron microscopy images of liposomes. The small black particles are artifacts produced during 
sample preparation for microscopy.
A
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and entrapment methods in order to improve PS-loaded 
liposomes. In general, the methods frequently employed to 
encapsulate PSs are rehydration of a thin lipid film (classic 
Bangham technique), ethanol injection and freeze/thawing 
(10-12). It should also be taken into account that the chosen 
method - sometimes involving mechanical energy, chemical 
reactions or temperature variation steps - should neither 
affect PS properties nor reduce its activity. 
The stability of the liposomes should also be evaluated 
since the association of PS with liposomes has been shown 
to alter the thermal phase behavior of the latter (10,13). This 
parameter is intrinsically dependent on the phospholipid-
specific phase transition temperature at which the molecules 
are reorganized from a rigid bilayer to a fluid bilayer. It has 
been reported that the association of the PS temoporfin 
resulted in a concentration-dependent decrease in the phase 
transition temperature of dipalmitoylphosphatidylcholine-
based liposomes (13). When the lipid composition was 
modified with phospholipids endowed with longer hydro-
phobic acyl chains (distearoylphosphatidylcholine), phase 
transitions were well above body temperature even at high 
PS load (13). Moreover, the lipid bilayer phase transition 
can also be modified with the addition of cholesterol, where 
increasing amounts of cholesterol increase liposome rigidity 
and stability in biologic fluids (13).
Photosensitizer liposome formulations
One of the first PSs used for cancer therapy consisted 
of a complex mixture of several partially unidentified por-
phyrins. Besides their effectiveness in PDT treatments, 
poor selectivity for diseased tissues, high dose, extended 
retention in the host organism, and low wavelength acti-
vation (630 nm) were the main drawbacks (7,14). These 
drawbacks stimulated the development of new PSs show-
ing fast elimination from the body, fewer side effects, and 
a higher absorption peak (650-800 nm) (6,7,15).
Despite the improvements achieved, these molecules 
present low solubility in physiological solutions (6,7,15). For 
instance, both phthalocyanines and chlorins are hydropho-
bic PSs that form aggregates in physiological solutions (16). 
When aggregated, the PSs are far less efficient in translating 
light energy into a chemical potential. This happens because 
the effect of quenching is amplified in these aggregates, 
i.e., the aggregated molecule is not able to absorb light or, 
even though it absorbs light, the photoexcited PS decays 
to the ground-state before producing singlet oxygen (16). 
Moreover, PS aggregates also hamper parenteral admin-
istration (such as intravenous injection) and the delivery of 
the PS drugs to targeted tissues (6,7). One may think that 
the use of a hydrophilic PS should minimize the drawbacks 
shown by hydrophobic PSs, but the hydrophilicity raises 
problems related to the interaction with biological tissues. In 
fact, it has been reported that the hydrophilic photosensitizer 
aminolevulinic acid (ALA) is not well internalized by cells 
and has no specificity for diseased tissues (6). Therefore, 
the use of PSs associated with nanoparticles could be an 
interesting approach in order to avoid PS aggregation and 
to deliver the PS into the target site. 
In this context, liposomes are suitable delivery systems 
for carrying hydrophilic or hydrophobic PSs, improving their 
clinical application (17). The liposome structure enables the 
entrapment of hydrophilic PSs in the aqueous core and the 
attachment of the hydrophobic ones to the phospholipid 
bilayer; consequently, the interaction of hydrophilic PSs 
with cells is enhanced and the hydrophobic PSs are kept 
in their monomeric configuration even in physiological 
aqueous media. In general, hydrophobic PSs have been 
attached to small unilamellar vesicles (20 to 100 nm) - 
whereas hydrophilic PSs have been entrapped in large 
unilamellar vesicles (100-500 nm) because of their large 
aqueous core (9,18).
Dermal delivery 
Superficial cutaneous tumor lesions are directly acces-
sible for topic application of PS molecules onto the disease 
site (12), minimizing eventual concerns involved in intrave-
nous administration. Nevertheless, the efficient penetration 
of the PS into skin layers is essential to achieve successful 
PDT results (12). Some studies have shown that liposomal 
formulations, associated with organic solvents, terpenes, 
edge activators (sodium cholate, polysorbate 80 or polysor-
bate 20) and ethanol, enhance PS penetration through the 
skin, even to an extent comparable to that of subcutaneous 
administration (12,19). This enhanced penetration feature 
is attributed to the high elasticity, small size and high flex-
ibility shown by these vesicles, which are therefore able 
to squeeze out through narrow constrictions of the skin 
layers and/or to interact with skin stratum corneum lipids, 
to solubilize these molecules and to create some channels 
enabling their permeation through the skin (12,19). 
Fang et al. (20), using an animal skin permeation 
protocol, evaluated ethosomes - liposomes containing a 
relatively high concentration of ethanol - as PS dermal 
delivery systems. The PS used was ALA, a precursor 
of the PS protoporphyrin IX (PpIX), formed in vivo after 
exogenous ALA application. The results showed that PpIX 
concentration in the inner skin layers was enhanced when 
ALA was carried by ethosomes compared to conventional 
liposomes. The same group investigated the permeation 
ability of topically applied ALA-containing ethosomes in a 
hyperproliferative mouse skin model. Ethosome vehicle 
formulation showed a 3.64-fold increase in PpIX detection 
in mouse skin when compared to ALA aqueous formulation 
vehicle (20). Dragicevic-Curic et al. (21) showed that the 
PS meta-tetrahydroxyphenylchlorin (mTHPC) associated 
with conventional liposomes showed lower skin penetration 
than ethosomes formulated with 20% ethanol. The same 
research group also reported a significant reduction in the 
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growth of the very invasive human colorectal carcinoma 
HT29 in mice after topical application of mTHPC associated 
with liposomes obtained by a combination of phospholipids, 
ethanol and terpenes (12). 
In order to improve dermal delivery, the association of 
liposome with ionophoresis (to enhance the flux of ionic 
compounds across the skin) has been suggested (22). 
Taken together, all the experiments described here show 
that it is possible to improve the topical delivery of PSs 
simply by incorporating new components into the liposome 
formulation, once more proving the versatility of this drug 
delivery system. Other liposomal formulations for topi-
cal drug delivery and their related patents are described 
elsewhere (23).
Intravenous delivery 
The interaction of conventional liposomes with a 
diseased tissue after intravenous administration is not 
immediate. Once administered by the intravenous route, 
the liposomes are exposed to several proteins, cells and 
tissues that can reduce or even totally prevent them from 
reaching their target site. For example, it is known that 
liposomes are rapidly eliminated from the bloodstream 
due to surface opsonization and later phagocytosis by the 
reticuloendothelial system (RES), a physiological system 
mainly consisting of macrophages resident in the liver, 
spleen and lymphatic system, responsible for the elimina-
tion of several macromolecules and particles from the body 
(22,24). Moreover, the interaction of liposomes with plasma 
lipoproteins - which destabilize the vesicles - significantly 
reduces the circulation time of liposomes in the bloodstream 
and promotes the leakage of the PS before it can reach 
the target site (17). 
The knowledge about the dynamics of particles adminis-
tered to the human body has led many researchers to sug-
gest interesting modifications in the structure/composition 
of liposomes in order to improve not only their stability but 
also their tissue selectivity and internalization. Particularly, 
there are some well-known questions regarding both the 
vasculature and the lymphatic clearance of particles at the 
tumor site that have created an entire line of improvements 
in antineoplastic liposome formulations. 
It is known that tumors are supplied by leaky vessels pre-
senting gaps between their endothelial cells (25). Because 
of this leaky vasculature, compounds and particles tend to 
migrate easily from the bloodstream to the diseased tissue. 
Furthermore, the presence of poor lymphatic drainage in 
these lesions also contributes to the enhanced retention 
time of the particles. Both the increased permeation and 
reduced clearance of particles in the tumor account for the 
passive accumulation of particles at the disease site, known 
as the ‘enhanced permeability and retention’ (EPR) effect 
(26). When the PSs are associated with liposomes ranging 
in size from 100 to 400 nm, the passive PS accumulation 
in the disease tissue is optimized (27). 
Nevertheless, the short circulation time of conventional 
liposomes (tens of minutes) in the bloodstream impairs their 
efficient accumulation at the disease site, which depends 
on the frequency at which the liposomes pass through the 
tumoral vessels. Some surface modifications have been 
suggested in order to reduce the interaction of liposomes 
with the immune system. Studies have demonstrated that 
the addition of a polymeric hydrophilic coat to the liposome 
surface significantly increases its half-life in the bloodstream 
by reducing the recognition and interaction with plasma 
proteins and RES macrophages (28,29). These long-
circulation liposomes are known as PEGylated liposomes, 
due to the use of polyethylene glycol as a coating agent. 
In fact, PEGylated liposomes have an extended half-life in 
the bloodstream in comparison to conventional liposomes 
and subsequently enhanced PS accumulation in diseased 
tissues by the EPR effect, as observed by Sadzuka et al. 
(30). These investigators reported a higher accumulation 
rate of the PS coproporphyrin I incorporated into PEGylated 
liposomes and an improved response to PDT treatment in 
mice when compared to conventional liposomes and/or to 
free PS. Similarly, Oku et al. (31) showed that 80% of mice 
bearing a subcutaneous sarcoma were cured after PDT 
treatment with intravenous injection of the benzoporphyrin 
derivative monoacid ring A (BPD-MA) incorporated into 
glucuronide-modified liposomes, while only a 20% cure rate 
was observed for injected PS-conventional liposomes.
Selectivity and dose improvement 
Besides prolonged bloodstream circulation time and 
notable tumor accumulation, some reports have claimed 
that the cell interaction/uptake of PS-PEGylated liposomes 
is low and consequently may lead to reduced PDT efficiency. 
For instance, Oku et al. (31) reported that the PEGylation of 
BPD-MA-liposomes enhanced the passive accumulation of 
the liposomal drug in tumor tissues at 3 h after administra-
tion, but did not enhance the PDT efficacy, suggesting that 
the liposomes were not effectively taken up by the tumor 
cells before laser irradiation. Moreover, the low interaction 
of PEGylated liposomes with cells also reduces the amount 
of reactive oxygen species (ROS) that reach the targeted 
cells, since ROS are generated at the PS activation site 
and then diffuse through short distances (about 0.02 µm) 
due to their short half-life in biological tissues (3). 
Besides the passive accumulation obtained by the 
EPR effect with liposomes within a certain size range, the 
conjugation of targeting molecules to the liposomal surface 
is an interesting alternative for obtaining a more specific 
localization of the PS, not only improving tissue selectivity 
but also reducing the effective PS concentration necessary 
to achieve successful PDT results (32). In contrast to the 
passive accumulation process, this approach is known as 
active targeting and is mainly used to specifically detect 
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tumor cells and vessels. Both the passive and active target-
ing can work together in accumulating the PS-containing 
liposome at the tumor site and specifically directing the PS 
to the tumor cells, respectively.
The active targeting to tumor cells can be based on the 
fact that tumor cells aberrantly overexpress certain tumor-
associated antigens that are found in low amounts or are 
even absent in non-tumor cells. Tumor cells overexpress, 
for example, receptors for vitamins (folate), growth factors, 
glycoproteins (transferrin) and glycolipids to support their 
high metabolic activity (7). Liposomes conjugated with these 
tumor-specific ligands have been developed for PS delivery 
in antineoplastic PDT. The treatment of cervical cancer 
cells overexpressing transferrin receptors with PEGylated 
liposomes conjugated with transferrin significantly increased 
the PS AlPcS4 cell uptake and was ten times more effective 
than the free AlPcS4 (33).
Several tumor-specific ligands are widely available, 
relatively inexpensive and minimally immunogenic (17). 
Nevertheless, their use demands a careful evaluation of the 
overexpressed receptors present in the tumor microenvi-
ronment to avoid reaching normal cells that often express 
receptors for the same ligands (17).
Internalization improvement
After the initial interaction of the liposome with the 
surface of the target cell, it is important that PS reaches 
the subcellular location that causes the desired damage to 
the target cell, be it cell death by apoptosis or by necrosis, 
or even just cellular stress. Internalization, instead of just 
adsorption, of the PS-containing liposomes by the cell is 
generally desired in order to induce more intense cell dam-
age. Most of the internalization strategies are focused on 
endocytotic processes, such as phagocytosis, or on the in-
vading mechanisms used by some intracellular parasites.
Viruses, for example, are endowed with fusogenic pro-
teins that are able to bypass the plasma membrane allowing 
the internalization of their genetic material (34). Fusogenic 
viral envelope proteins and cell penetrating peptides, such 
as TAT (from the HIV virus), are positively charged molecules 
able to adhere to the target cell by electrostatic attraction 
since the cell membrane possesses an overall negative 
charge (35). This viral strategy has inspired researchers 
to design liposomes containing cationic lipids or cationic 
peptides/polymers coupled to their surface, which have been 
shown to be interesting models for the delivery of PS due 
to the enhanced effective tissue penetration (7). 
Molinari et al. (36) reported that the internalization of 
the PS m-THPC in malignant glioma cells was significantly 
enhanced when cationic liposomes were used as carriers. 
Takeuchi et al. (37) designed a cationic polyethylenimine-
modified liposome encapsulating the PS BPD-MA for anti-
angiogenic PDT and reported that the cationic liposomes 
maintained their phototoxicity to endothelial cells while the 
effect of non-modified liposomes was suppressed (37,38). 
Another study by the same research group also reported 
the destruction of angiogenic vessels and the subsequent 
apoptosis of tumor cells after iv injection of a low dose of 
cationic BPD-MA-liposomes on sarcoma-bearing mice 
(39). 
Although the internalization mechanism for liposomes 
is not fully known, the process of endocytosis has been 
described as one of the most common pathways by which 
these particles are internalized by cells (35,40). A remark-
able characteristic of this process, which must be taken 
into account when designing PS-containing liposomes, is 
that endosome vesicles entrapping liposomes fuse with the 
lysosome, which contains enzymes in an acid aqueous en-
vironment, before the PS is released in significant amounts 
to the cytosol (40). Thus, the endosomal/lysosomal pathway 
can potentially damage the PS and, consequently, reduce 
their effectiveness. In this context, a potential advantage of 
cationic liposomes, which is also explored by some viruses, 
is that they can fuse with the endosome membrane and then 
release their content directly into the cytoplasm, preventing 
it from being degraded by lysosomal enzymes (35).
The use of cationic liposomes increases the efficiency of 
S internalization for PDT treatment, thus reducing the total 
therapeutic dose needed. Nevertheless, cationic liposomes 
do not present any selectivity for specific cells - unless that 
mediated by surface charge - and they may in fact fuse with 
almost all types of mammalian cells (35). In order to obtain 
tumor selectivity and assure low side effects, the combina-
tion of cationic molecules and active-targeting moieties is 
necessary (41). In addition, the exact proportion of positively 
charged polymers and/or phospholipids to be added to a 
liposome formulation must be correctly calculated, since 
the fraction of positively charged molecules in a liposome 
is likely to be critical for its effective delivery, cell uptake 
and toxicity (35).
Liposomal formulations currently in clinical 
use
Several pharmaceutical companies are investigating 
new PSs, PS delivery vehicles, and PDT protocols for the 
treatment of different tumors (3,7). Only one liposomal for-
mulation has been approved thus far by the FDA for clinical 
application in PDT, but it is not designed for antineoplastic 
treatment. This formulation, with the registered trademark 
Visudyne®, contains BPD-MA, verteporfin and a 1:1 mixture 
of the structural isomers BPD-MAC and BPD-MAD (42). 
It is a reconstitutable lyophilized powder for intravenous 
infusion, indicated for the treatment of age-related macu-
lar degeneration in patients with predominantly classic 
subfoveal choroidal neovascularization. The rationale of 
the Visudyne® therapy relies on the elimination of the 
neovasculature - responsible for the macular degeneration 
- after vascular occlusion elicited by the endothelial damage 
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Tumor cells are more sensitive to temperatures in the 
range of 38-45°C than normal cells. This characteristic has 
led to the development of hyperthermia therapy, which is 
based on the heating of tumor tissue in order to kill neo-
plastic cells. The association of PDT and hyperthermia in a 
single therapy has been proposed and encouraging results 
have already been published (43). This is an interesting 
approach because one treatment complements the other 
as oxygenated tumor cells are preferentially killed by PDT 
while hypoxic cells are preferentially killed by hyperthermia 
(44,45). Therefore, besides the advantages of liposomes 
in PDT itself, this type of drug delivery system could also 
be used to carry hyperthermia agents such as superpara-
magnetic nanoparticles, associated with PSs, an approach 
that has a great potential to improve tumor cell death rates. 
Nevertheless, to our knowledge, such studies employing 
liposomes still remain to be done.
Magnetoliposomes 
The entrapment of magnetic nanoparticles into PS-
containing liposome carriers is another promising approach 
to tissue-specific PS targeting, given that a magnetic field 
can be used to selectively accumulate the PS-magnetic lipo-
some in a certain tissue (22). Oliveira et al. (46) described 
the characterization of a magnetic liposome entrapping the 
PS zinc phthalocyanine and reported that the photophysical 
and photochemical properties of the PS were very close to 
the characteristics of an ideal PS compound. Aside from 
encouraging results, the effects of PS-magnetic liposomes 
in in vivo tumor models have not been reported, indicat-
ing that further improvements are needed for this kind of 
liposomal formulations. 
Immunization 
Most of the antineoplastic treatments induce a large 
destruction of the tumoral mass, but generally they are 
not capable of totally eliminating it, often due to the tumor 
idiosyncrasy or to the limited range of treatment. PDT itself 
can lethally damage over 90% of the neoplastic cells in 
tumors (47), but the remaining viable neoplastic cells are 
still capable of maintaining the tumor growth after PDT, 
representing a potential possibility for tumor recurrence. 
Taking into account only this acute effect, PDT could be 
viewed only as a co-therapy but not as a main antineoplastic 
approach. However, the effects of PDT go far beyond the 
more discussed light-induced oxidative damage in the cells; 
they do affect the structure and function of the tissue in which 
the cell is located and, often, the whole organism.
The cellular debris along with the inflammatory environ-
ment elicited at the site of PDT application are responsible 
for a potential long-lasting effect, which can be more im-
portant than the direct cell killing itself, i.e., the activation 
of the adaptive immune system against tumoral antigens 
(47). This event can be responsible for the destruction not 
only of all neoplastic cells in the treated tumor, but also of 
those metastatic neoplastic cells sharing antigens with the 
PDT-damaged ones. Experimental evidence supports this 
rationale (48). The classical study by Korbelik et al. (49) 
showed that, although the acute antineoplastic PDT effect 
was the same in both immunocompetent and immunode-
ficient individuals, the long-term protection against tumor 
recurrence was obtained only in immunocompetent mice, 
demonstrating the crucial role played by the immune system 
after PDT application. 
The mechanisms behind the PDT-induced immunization 
are not fully understood but several studies relate cellular 
stress and damage to the subsequent immunization. The 
cellular debris at the site of PDT application are strong induc-
ers of the immune system and their immune adjuvanticity 
seems to be dependent on the danger signals, which are 
discussed in detail elsewhere (50,51). The danger signals 
are often related to cell stress/damage and are capable 
of eliciting strong inflammatory responses (52). The cells 
subjected to PDT undergo a characteristic stress response, 
increasing the expression of stress molecules, such as 
heat-shock proteins (53). The lysis of these stressed cells 
occurs within minutes to hours after PDT application, re-
leasing several stress proteins along with other intracellular 
components such as ATP, which function as danger signals. 
These danger signals promote the activation of the dendritic 
cells (DCs) present at this site, which then become capable 
of migrating to the draining lymph nodes and activating ef-
fector functions on T cells specific for the tumoral antigens 
(47,50). In addition to DCs, other antigen-presenting cells 
at the PDT application site can be responsible for the local 
reinforced activation of the adaptive immune system.
Another significant event following PDT is the direct 
ROS-mediated activation of inflammatory signaling path-
ways, such as those leading to the formation of inflam-
masome complexes (47,52), which play a critical role in 
immunization. The production of ROS can be directly or 
indirectly promoted by PDT. The direct stimulation is re-
lated to the classical generation of singlet oxygen after PS 
photoactivation, previously cited as Type II reaction. By the 
indirect pathway, the cellular debris, along with the danger 
signals released by damaged cells, elicit the oxidative burst 
by inflammatory cells (47). Therefore, both the PDT-induced 
oxidative burst and the danger signals can be viewed as 
important adjuvants for the process of immunization. 
However, despite the important immune adjuvanticity 
exerted by the cellular debris, some studies have related 
the local application of exogenous immune adjuvants to a 
significant improvement of PDT-induced tumor immuniza-
tion (54). This finding suggests that formulations containing 
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